Replies to post #100186 on Biotech Values

[DewDiligence]

ANDS update on ANA598/ANA773:

We are currently finalizing preparations for a Phase IIb study of ANA598 in combination with current standard of care in treatment-naïve and treatment-experienced patients. The Phase IIb study design is intended to support a broad range of potential treatment opportunities in future Phase III studies.

We also plan to augment our HCV development pipeline in the first half of next year by initiating a Phase IIa study of ANA773, our oral inducer of endogenous interferons.

http://finance.yahoo.com/news/Anadys-Pharmaceuticals-prnews-1641637649.html?x=0&.v=1

ANDS must truly be desperate to be talking about resuscitating ANA773, the TLR7 modulator that ANDS effectively discontinued 1.5 years ago (#msg-38418158). I completely discount the potential for ANA773 to be a meaningful drug in HCV.

As of 9/30/10, ANDS had $42.7M in cash on a pro forma basis including the proceeds of the Oct 2010 financing (#msg-55600174).